anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cutaneous melanoma (cM) is a prevalent invasive cancer resulting from the malignant transformation of melanocytes. At present, the primary treatment for melanoma is surgical resection, which is not appropriate for patients with metastasis. Therefore, it is necessary to identify effective therapeutic targets for the early diagnosis and treatment of metastatic melanoma. Acyl-CoA thioesterase 7 (ACOT7) has been reported to be involved in the progression of multiple cancer, while its role in melanoma has not been extensively researched. Through gain-of-function and loss-of-function experiments, ACOT7 was identified as a tumor promoter that facilitates the progression of melanoma cells. Cell proliferation was promoted by overexpressing ACOT7 in M14 cells, and was suppressed by silencing ACOT7 in MeWo cells. Knockdown of ACOT7 induced cell cycle arrest by increasing the expressions of cyclin dependent kinase inhibitor 1B (P27) and cyclin dependent kinase inhibitor 1 A (P21), while simultaneously reducing proliferating cell nuclear antigen (PCNA) expression. Upregulation of ACOT7 promoted the cell cycle of melanoma cells. Additionally, apoptosis was induced by the absence of ACOT7 through activating caspase-3 and poly (ADP-ribose) polymerase (PARP). The metastatic and invasive capacity of melanoma cells was significantly enhanced by the overexpression of ACOT7 and inhibited by the downregulation of ACOT7. Moreover, the cAMP responsive element binding protein 1 (CREB1) positively regulates ACOT7 expression by binding to its promoter region. A decrease of cell proliferation, migration and invasion, as well as an increase of cell apoptosis induced by silencing CREB1 were obviously reversed by ACOT7. In summary, ACOT7 transcriptionally activated by CREB1 elevates the progression of cM.
The general aim of this study was to determine the neuroanatomic basis for cognitive pathology in schizophrenia, as well as the effects of treatment with typical and atypical antipsychotics on clinical symptoms, neurocognition and brain function, as measured with function magnetic resonance imaging. Subjects underwent a randomized parallel group treatment trial that consisted of: a four-week Thiothixene treatment period, followed by randomization, two-weeks cross titration, and six-weeks of double blind treatment with Risperidone (RIS) or Olanzapine (OLZ). Twenty-three patients with schizophrenia or schizoaffective disorder and fifteen healthy control subjects were initially enrolled. Diagnosis was established with the SCID. Subjects were assessed at two time points, at baseline after four weeks of Thiothixene treatment and at follow up, after eight weeks of double-blind atypical antipsychotic treatment. Controls were assessed once. Symptom severity was assessed using the PANSS. Cognitive functions associated with frontal and temporal cortical regions were probed with a neurocognitive testing battery using standardized attention, executive function and working memory tasks. Frontal and temporal cortical function was assessed with fMRI during the performance of visual and auditory oddball tasks. The visual task oddball task consisted of identifying an infrequent square presented within a series of frequent squares. The auditory oddball task consisted of identifying an infrequent pitch-deviant target tone embedded within a series of frequent standard tones. Thirteen patients and eleven controls completed fMRI at baseline and follow-up.

The results indicated that patients treated with the typical neuroleptic Thiothixene showed significantly smaller extents of activations in superior temporal, anterior cingulate and thalamic regions as compared to control subjects during the auditory oddball task. Although treatment with atypical neuroleptics considerably reduced group differences in cortical activation between controls and patients, the current sample size proved to be insufficient to yield statistically significant group by time interactions. The percent signal change data was in the same direction, but proved to be less sensitive to group differences than the extent of activation. The group differences were not pronounced during the visual oddball task, but were in the same direction.
The present application relates to a user interface for fitness content. In some embodiments, the electronic device performs techniques that involve displaying personalized fitness recommendations based on the completed fitness. In some embodiments, an electronic device performs a technique that involves initiating audio-based fitness. In some embodiments, the electronic device performs techniques that involve displaying information about the workout during playback of the workout content. In some implementations, an electronic device performs techniques that involve displaying information about physical activity of a user relative to a group of users. In some embodiments, an electronic device performs techniques that involve coordinating the display of fitness content among multiple devices.
A significant increase in the worldwide incidence and prevalence of type 2 diabetic mellitus (T2DM) has elevated the need for studies on novel and effective therapeutic strategies. Sirtuin 1 (SIRT1) is an NAD + dependent protein deacetylase with a critical function in the regulation of glucose/lipid metabolism, insulin resistance, inflammation, oxidative stress, and mitochondrial function. SIRT1 is also involved in the regulation of insulin secretion from pancreatic β-cells and protecting these cells from inflammation and oxidative stress-mediated tissue damages. In this regard, major SIRT1 activators have been demonstrated to exert a beneficial impact in reversing T2DM-related complications including cardiomyopathy, nephropathy, retinopathy, and neuropathy, hence treating T2DM. Therefore, an accumulating number of recent studies have investigated the efficacy of targeting SIRT1 as a therapeutic strategy in T2DM. In this review we aimed to discuss the current understanding of the physiological and biological roles of SIRT1, then its implication in the pathogenesis of T2DM, and the therapeutic potential of SIRT1 in combating T2DM.
B-1a cells, an innate-like cell population, are crucial for pathogen defense and the regulation of inflammation through their release of natural IgM and IL-10. In sepsis, B-1a cell numbers are decreased in the peritoneal cavity as they robustly migrate to the spleen. Within the spleen, migrating B-1a cells differentiate into plasma cells, leading to alterations in their original phenotype and functionality. We discovered a key player, sialic acid-binding immunoglobulin-like lectin-G (Siglec-G), which is expressed predominantly on B-1a cells and negatively regulates B-1a cell migration to maintain homeostasis. Siglec-G interacts with CXCR4/CXCL12 to modulate B-1a cell migration. Neutrophils aid B-1a cell migration via neutrophil elastase (NE)-mediated Siglec-G cleavage. Human studies revealed increased NE expression in septic patients. We identified an NE cleavage sequence in silico, leading to the discovery of a decoy peptide that protects Siglec-G, preserves peritoneal B-1a cells, reduces inflammation, and enhances sepsis survival. The role of Siglec-G in inhibiting B-1a cell migration to maintain their inherent phenotype and function is compromised by NE in sepsis, offering valuable insights into B-1a cell homeostasis. Employing a small decoy peptide to prevent NE-mediated Siglec-G cleavage has emerged as a promising strategy to sustain peritoneal B-1a cell homeostasis, alleviate inflammation, and ultimately improve outcomes in sepsis patients.
Pelvic inflammatory disease (PID) is a spectrum of upper genital tract inflammations comprising endometritis, salpingitis, parametritis, oophoritis, tubo-ovarian abscess and/or pelvic peritonitis. The objectives of administering antimicrobial therapy in patients with PID are to control the symptoms and to prevent the late sequelae of the disease. Because anaerobe infections (e.g., Bacteroides fragilis infections) are associated with tubal and epithelial damage, anaerobic coverage is routinely recommended in women with pelvic infection. Guidelines have been developed in both the USA and Europe with regard to PID management. Metronidazole, a member of the nitroimidazole drug class, is included in the regimens recommended for improving anaerobic bacteria coverage. The sideeffects of metronidazole include a metallic taste, nausea, transient neutropenia, and peripheral neuropathy. Antimicrobial resistance to metronidazole has emerged after several decades of worldwide use of the drug. Morinidazole, a National Class I Antimicrobial, is a new type of third-generation nitroimidazole antimicrobial that is used for treating amoebiasis, trichomoniasis, and anaerobic bacterial infections, and which exhibits greater activity and less toxicity than metronidazole.

Morinidazole and Sodium Chloride Injection used in PID or appendicitis cases had been approved by CFDA in 2014. This phase 4 study is to assess the efficacy, safety and Population Pharmacokinetic (PPK) of morinidazole in PID.
A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.
An excellent squalene synthase inhibitor is provided. Specifically, what is provided is a compound (I) represented by the following formula, a salt thereof or a hydrate of them. In formula (I), R 1  represents an optionally substituted vinyl group or an aromatic ring which may be substituted. Also, n is an integer of 0 to 2. Further, X, Y and Z are the same as or different from each other and each represents an optionally substituted carbon atom, or an optionally substituted nitrogen atom, sulfur atom or oxygen atom, and Y optionally represents a single bond, and when Y represents the single bond, the ring to which X, Y and Z belong is a 5-membered ring. Also in the formula, CyA represents a 5- to 14 membered non-aromatic cyclic amino group or non-aromatic cyclic amido group which may be substituted, and the non-aromatic cyclic amino group or the non-aromatic cyclic amido group optionally having an oxygen atom or a sulfur atom. Finally, W represents a chain
All major patients under 70 years of age with cirrhosis and portal hypertension justifying a treatment with TIPS. These patients must be affiliated to a social security and able to sign a free, informed and written consent.
The invention relates to an external preparation for prospermia and the preparation method thereof. The external preparation for the prospermia is prepared by the following medicament raw materials according to weight ratio: 200-300 parts of gallnut, 180-260 parts of wild ginger, 170-240 cnidium fruit, 155-235 parts of ephedra, 135-255 parts of pepper stem and 0.15-0.45 parts of camphor. The external preparation for the prospermia extracts the effective constituents in the medicament raw materials by using a water cooking and extraction method and keeps the activity thereof. Therefore, the dissolution rate of the effective constituents in the medicament is improved greatly, and the medicament can be absorbed effectively, thereby improving the bioavailability. In addition, the medicine of the invention is a pure traditional Chinese medicine preparation, so that no toxic and side effects are existent after a patient uses for a long time, and the preparation has good safety. Moreover, the preparation method of the invention has the advantages of simple process and convenient operation.
The invention discloses an esomeprazole magnesium micro-tablet, which is provided with a cylindrical space shape. The height of the esomeprazole magnesium micro-tablet is 1-3mm, and the diameter of the esomeprazole magnesium micro-tablet is 1-3mm. The content of the esomeprazole magnesium which is the active ingredient in the micro-tablet is 1-5mg, and the adopted enteric coating material is methacrylic acid copolymer (Eudragit L100). The enteric coating material of the esomeprazole magnesium micro-tablet also comprises triethyl citrate which is used as plasticizer, the content of the triethyl citrate is 0.05-0.08mg, glidant is glycerin monostearate, the content of the glycerin monostearate is 0.1-0.15mg, surfactant is polysorbate, and the content is 0.1-0.2mg. The micro-tablet and acceptable pharmaceutic adjuvants are prepared into the esomeprazole magnesium tablet, and the acceptable pharmaceutic adjuvants consist of lactose, croscarmellose sodium, polyvinylpyrrolidone and talcum powder. The esomeprazole magnesium micro-tablet disclosed by the invention can be used for treating the digestive tract ulcer disease.
Hemoglobin E (HbE) is distinguished from normal HbA by a single amino acid mutation (beta26: Glu to Lys). High allele frequencies in some areas of Cambodia are believed to have been naturally selected by life-threatening manifestations of malaria. Few epidemiological studies support this hypothesis, however, and in vitro studies have not clearly defined a mechanism of protection. The prevalence of drug-resistant malaria is alarmingly high along the Thai-Cambodian border, such that chloroquine, quinine, or mefloquine can no longer effect acceptable cure rates. Recently, prolonged parasite clearance times after artemisinin treatment have been documented in Battambang and Pailin provinces in Cambodia. Combinations of artemisinins and other drugs (e.g., mefioquine, piperaquine) are now used as standard first-line treatments for P. falciparum malaria in Southeast Asia. Further decreases in the effectiveness of these drugs would constitute a disaster, making some cases of malaria essentially untreatable. The molecular basis for parasite resistance to these antimalarials has not been firmly established. The main aims of this study are to (1) determine whether HbE protects against severe P. falciparum malaria, (2) identify genetic determinants associated with parasite resistance to antimalarial drugs, and (3) determine whether HbE and other erythrocyte polymorphisms influence parasite clearance times after artemisinin treatment. To meet these aims, we are conducting an unmatched case-control study comparing the prevalence of HbE in patients with severe and uncomplicated P. falciparum malaria. Cambodians who complain of fever and/or symptoms of malaria are recruited from Pursat Regional Health Center and surrounding districts within Pursat Province. Patients with uncomplicated malaria are treated with weight-based doses of artesunate given orally each day for 3 days, followed by weight-based doses of mefloquine given orally each day for 2 days. Patients with severe malaria will be treated with artemisinin compounds given parenterally for 5 consecutive days, followed by artesunate plus mefioquine treatment, as above. We will also collect parasitized blood samples from malaria patients prior to antimalarial drug administration. These parasites will be tested in short-term in vitro culture experiments to determine their susceptibility to antimalarial drugs. Genome-wide typing of drug-sensitive and drug-resistant P. falciparum isolates (using microsatellite and single nucleotide polymorphism markers) and genetic association studies will be used to identify genes that determine parasite responses to various antimalarial drugs.
Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
PURPOSE:To obtain a new polypeptide having a specific amino acid sequence, which is produced by and excreted from a human glioblastoma cell line, useful for e.g. an agent for prophylaxis and/or treatment of dysgenesis or abnormal growth of cell, hypergasia or hyperergasia, tumor, etc. CONSTITUTION:A human glioblastoma cell line T98G is stimulated with human interleukin-1beta and then the entire RNAs are recovered from the stimulated cell line by an ordinary method. The recovered RNAs are fractionated through an oligo-dT- cellulose column to collect mRNAs. cDNAs are synthesized by a reverse transcriptase using the obtained mRNAs as templates and a cDNA l-ibrary is produced using the cDNAs. Subsequently, this library is cloned to select positive clones. Plasmids are recovered from the cells obtained by culturing the positive clones and the plasmids are bound to vectors after the restriction enzyme treatment. The plasmid-bound vectors are introduced to host cells to perform transformation and these transformed cells are cultured. The objective new polypeptide consisting of the amino acid sequence expressed by the formula, its homolog, its fragments, etc., are obtained from the cultured mixture.
The invention discloses ultra-small Fe  3  O  4  Nanoparticle self-assembly nanoclusters and a preparation method and application thereof. The invention utilizes the oil-thermal method to decompose the complex of organic matters and iron ions at high temperature to obtain the ultra-small Fe with the size less than 5nm  3  O  4  Nanoparticles, ultra-small Fe modified with dispersant of good water dispersibility  3  O  4  Nano particles, so that the water-dispersible nano particles have good water dispersibility. Simultaneously ultra-small Fe  3  O  4  The nanoparticles self-assemble while dispersing, resulting from assembling nanoclusters. Ultra-small Fe  3  O  4  Nanoparticle self-assembled nanoclusters with ultra-small Fe  3  O  4  The ultra-small size of the nanoparticles makes them have good T  1  MRI imaging effects of the modality. Self-assembly into nanoclusters of about 10-100 nm simultaneously, and T is enhanced  2  MRI imaging effect of modality, thus having T  1  /T  2  A bimodal imaging effect. The preparation method adopted by the invention has the advantages of material benefit, good biocompatibility, strong magnetism, good dispersibility, suitability for large-scale production, green and pollution-free synthesis method, and wide application prospect in the fields of biomedicine and clinical medicine.
OBJECTIVE: This study aims to investigate the occurrence of postoperative kinesiophobia in patients with CSM and compare the postoperative recovery of patients with and without kinesiophobia to understand its influence on clinical outcomes in CSM.
METHODS: Between November 2020 and November 2022, surgical treatment was performed in the neurosurgical wards of 2 Grade III Class A general public hospitals in the Fujian Province. The demographic and disease data of the patients were collected, and patients were divided into a kinesiophobia group and non-kinesiophobia group according to the Tampa kinesiophobia Scale (TSK). The cervical dysfunction index, cervical Japanese Orthopaedic Association (JOA) rating, self-anxiety rating, and activity of daily living rating scales were collected three months postoperatively. The influence of postoperative kinesiophobia on early rehabilitation was also analysed.
RESULTS: A total of 122 patients were an average age of (55.2 ± 10.3) years included in this study. The average score of kinesophobia after surgery was 41.2 ± 4.5, with an incidence of 75.4%. Multivariate logistic regression analysis showed that age (OR = 1.105, 95% CI = 1.014-1.204), neck disability index (NDI) (OR = 1.268, 95% CI = 1.108-1.451), diabetes mellitus (OR = 0.026, 95% CI = 0.001-0.477), and Japanese Orthopaedic Association (JOA) score (OR = 0.698, 95% CI = 0.526-0.927) were associated with the occurren.
CONCLUSION: Doctors should be aware of kinesiophobia in patients with CSM. Education regarding kinesiophobia, strategies to avoid it, and treatment strategies using a multidisciplinary approach can improve recovery outcomes.
A detergent composition for use in the treatment of hair comprises a mixture of hydrogen peroxide and a liquid ammonium soap to which has been added a dry powder comprising a persulphate salt of a cation selected from alkali metals and ammonium, and an anhydrous alkali metal silicate, the silicate and persulphate salts being present in a weight ratio range of 1 : 4 to 1 : 7 and forming upon wetting with the liquids a gel in the pH range of from 9.3 to not more than 10. The liquid ammonium soap may be produced by the reaction of ammonium hydroxide and oleic, myristic, palmitic, lauric or stearic acid. Ammonium or potassium persulphate or a mixture thereof preferably containing approximately three parts by weight of potassium persulphate to one part of ammonium persulphate is preferably used. The composition may also contain wetting agents, e.g. isopropyl naphthalene sodium sulphonate, the dioctyl ester of sodium sulpho-succinic acid, alkyl aryl sodium sulphonates, sodium lauryl sulphate, nonylphenoxypoly (ethyleneoxy) ethanol and polyoxyethylene lauryl ether, dyes, chelating agents, e.g. N,N-di(2-hydroxy ethyl) glycine monosodium salt, perfumes and alcohol. The solid and liquid components of the composition may be packaged separately.ALSO:A dry powder for admixture with hydrogen peroxide and a liquid ammonium soap to form a hair bleach of gelatinous consistency comprises a persulphate salt of a cation selected from alkali metals and ammonium, and an anhydrous alkali metal silicate, the silicate and persulphate salts being present in a weight ratio range of 1:4 to 1:7 and forming upon wetting with both of the liquids a gel in the pH range of from 9.3 to not more than 10. The liquid ammonium soap may be produced by the reaction of ammonium hydroxide and oleic, myristic, palmitic, lauric or stearic acid.  Ammonium or potassium persulphate or a mixture thereof preferably containing approximately three parts by weight of potassium persulphate to one part of ammonium persulphate is preferably used.  The treating composition may also contain wetting agents, e.g. isopropyl naphthalene sodium sulphonate, the dioctyl ester of sodium sulphosuccinic acid, alkyl aryl sodium sulphonates, sodium lauryl sulphate, nonylphenoxypoly (ethyleneoxy) ethanol and polyoxyethylene lauryl ether, dyes, chelating agents, e.g. N,N - di(2 - hydroxyethyl)glycine monosodium salt, perfumes and alcohol.  The bleaching composition may be used for touch up purposes in bleaching new hair growth close to the scalp or for a total bleach and may be removed from the hair after the necessary bleaching process by the addition of water.  The liquid and solid components may be packaged separately.
Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA \[RO0503821\]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of \<40, 40-80, and \>80 mcg, respectively.